Hepatitis B virus X protein (HBx) plays a crucial role in the development of hepatocellular carcinoma (HCC). However, the significance of circulating antibody to hepatitis B virus X antigen (anti-HBx) in sera remains unclear. In the present study, we examined the titers of anti-HBx (IgG) in the sera from 173 patients with chronic hepatitis B (CHB), 106 liver cirrhosis (LC), and 61 HCC by enzyme-linked immunosorbent assay (ELISA), respectively. Our data showed that the positive rates of anti-HBx were higher in sera of LC (40.6) and HCC (34.4) than those of CHB (10.4), P <.05. In all 40 patients with anti-HBx+ out of 340 patients, 39 (97.5) were HBsAg/HBeAg/anti-HBc+ and 1 (2.5) was anti-HBs+ (P <.01), suggesting that anti-HBx in sera is a marker of HBV replication rather than a protective antibody. Thus, our findings reveal that circulating anti-HBx in sera is one of the markers of development of LC and HCC mediated by HBV. Copyright © 2009 Hang Zhang et al.
Ye, L. H., Zhang, H., Wu, L. Y., Zhang, S., Qiu, L. Y., Li, N., … Zhang, X. D. (2009). Anti-Hepatitis B Virus X protein in sera is one of the markers of development of liver cirrhosis and liver cancer mediated by HBV. Journal of Biomedicine and Biotechnology, 2009. https://doi.org/10.1155/2009/289068